Filing Analysis
Coherus Oncology, Inc. dismissed Ernst & Young LLP (EY) as its independent registered public accounting firm and appointed PricewaterhouseCoopers LLP (PwC) effective June 12, 2026.
🚩 Red Flags
- Change of auditor is always a point of scrutiny in micro-cap companies, though the lack of disagreements reduces immediate alarm.
📋 Key Facts
- Dismissal of Ernst & Young LLP (EY) effective June 12, 2026.
- Appointment of PricewaterhouseCoopers LLP (PwC) for the fiscal year ending December 31, 2026.
- Company states there were no 'disagreements' or 'reportable events' with EY during the fiscal years 2024, 2025, or the interim period through June 12, 2026.
- A prior material weakness in internal control over financial reporting regarding inventory account reconciliations (reported in FY2024) was stated as remediated in the FY2025 Annual Report.
Coherus Oncology, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 27, 2026, and a partially adjourned meeting on May 29, 2026. All five proposals, including director elections, auditor ratification, and equity plan increases, were approved.
🚩 Red Flags
- Proposal 4 (reduction of stock option exercise prices) can sometimes be viewed as a red flag regarding previous option pricing or employee retention, though it was approved by shareholders.
📋 Key Facts
- Annual Meeting held May 27, 2026; partially adjourned to May 29, 2026, specifically for Proposal 4.
- Proposal 1: Elected Dennis M. Lanfear and Mats L. Wahlström to the Board until 2029.
- Proposal 2: Ratified Ernst & Young LLP as the independent auditor for fiscal year ending Dec 31, 2026.
- Proposal 3: Approved non-binding 'Say-on-Pay' executive compensation.
- Proposal 4: Approved the reduction in the exercise price of certain outstanding stock options.
- Proposal 5: Approved an increase in common stock reserved for the Amended and Restated 2014 Equity Incentive Award Plan.
Coherus Oncology, Inc. reported its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The report date and the date of the earliest event reported is May 11, 2026.
- The filing covers financial results for the fiscal quarter ended March 31, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the full text of the earnings press release.
Coherus Oncology, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
📋 Key Facts
- The filing reports financial results for the period ended December 31, 2025.
- The report was filed on March 9, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The report was signed by CEO Dennis M. Lanfear.